VITAMIN D3 LACTONE DERIVATIVES

• Main Authors: TAKENOUCHI, KAZUYA, TAKAYAMA, HIROAKI, ANZAI, MIYUKI, SAITO, HIROSHI, FUJISHIMA, TOSHIE, KITTAKA, ATSUSHI, OKADA, KAZUHISA, ISHIZUKA, SEIICHI, MIURA, DAISHIRO, SAITO, NOZOMI
• Format: Patent
• Language: English; French
• Published: 13.09.2011
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

A compound represented by the following Formula (1) that is effective for the treatment of Paget's disease of bone or hypercalcemia or a medically acceptable solvate thereof; (see formula 1) [wherein R1 refers to hydrogen atom, C1-C6 alkyl group optionally substituted with hydrogen group or CI-C6 alkoxy group optionally substituted with hydroxyl group, R2a and R2b refer to hydrogen atom, C1-C10 alkyl group optionally substituted with hydroxyl group, C6-C10 aryl group optionally substituted with hydroxyl group or C7-C12 aralkyl group optionally substituted with a hydroxyl group, or are combined to represent ethylene group. However, a compound in which R1 is a hydrogen atom or a methyl group and R2a and R2b are hydrogen atoms is excluded]. L'invention concerne un composé représenté par la formule (1) ou un solvate pharmaceutiquement acceptable dudit composé. Ces composés sont efficaces pour le traitement de la maladie osseuse de Paget ou de l'hyperpotassémie. Dans la formule (1), R?1¿ représente hydrogène, alkyle C¿1-6? éventuellement hyroxylaté ou alcoxy C¿1-6? éventuellement hyroxylaté et R?2a¿ et R?2b¿ représentent chacun hydrogène, alkyle C¿1-10? éventuellement hyroxylaté ou aralkyle C¿7-12? éventuellement hyroxylaté ou R?2a¿ et R?2b¿ combinés représentent éthylène, à la condition que les composés dans lesquels R?1¿ représente hydrogène ou méthyle et R?2a¿ et R?2b¿ représentent hydrogène soient exclus.